

AI:AM — Human Tissue Models, Physical AI, and the Future of Testing · September 25, 2026
Vivodyne’s Andrei Georgescu explains how vascularized human tissue models, robotics, multi-omic measurement, and foundation models could improve drug testing before clinical trials. Archetype AI’s Nick Gillian discusses Newton, a Physical AI model that combines sensor data to understand and predict events in the real world; the hosts also examine AI product safety, OpenAI and Anthropic’s alignment philosophies, CRISPR research, and whether AI can deliver useful advances in biology before it is fully understood. Chapters (0:00) AI safety has two different meanings. (0:15) Why drug testing needs human tissue. (3:20) Physical AI is bigger than robots. (5:01) Biology’s bar is lifesaving progress. (11:17) Opening and AI news (11:38) Jensen Huang’s safety argument (13:24) The “just software” debate (15:31) Why AI companies must mature (21:12) Muse and product safety (29:25) Testing AI agents in the real world (29:35) Product safety versus existential risk (29:45) The alignment philosophy problem (38:34) OpenAI versus Anthropic (40:36) When safety concerns converge (41:55) Human tissue models (44:12) Why organoids need realism (47:35) Measuring tissue responses (54:03) Mapping causal biology (1:03:40) Improving drug development (1:09:08) Foundation models and experiments (1:12:18) TissueDisk and robotic labs (1:12:28) Before clinical trials (1:30:37) What is Physical AI? (1:32:25) Beyond robots and cars (1:35:33) Training on physical data (1:38:04) Cleaning and aligning sensor data (1:40:34) Human and machine outputs (1:49:30) A river construction case study (1:53:28) How Newton finds hidden patterns (1:57:33) Zero-shot sensor adaptation (2:01:16) Industrial impact and expert knowledge (2:05:22) From machines to ecosystems (2:14:10) Physical agents and superintelligence (2:15:34) The big AI-biology question (2:21:55) Specialists versus generalists (2:23:39) Distilling frontier models (2:33:33) AI discovers a CRISPR sequence (2:39:22) Useful biology before theory (2:45:10) From job displacement to progress (2:46:44) AI diffusion and economic growth Guests Andrei Georgescu — CEO, Vivodyne (𝕏 | LinkedIn) Nick Gillian — CTO, Cofounder, Archetype AI (𝕏 | LinkedIn) This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit briefing.ai-in-the-am.com


















